Shanghai Pharmaceuticals Holding (601607.SH): Lurcotinib Tablets have been approved for production.

Shanghai Pharmaceuticals Holding (601607.SH) announced that recently, its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. received the "Drug Registration Certificate" (Certificate Numbers: 2026S03098, 2026S03096, 2026S03097) issued by the National Medical Products Administration for Ruxolitinib Phosphate Tablets, and the drug has been approved for production. Ruxolitinib Phosphate Tablets are indicated for: 1. Myelofibrosis. For adult patients with intermediate- or high-risk primary myelofibrosis (PMF) (also known as chronic idiopathic myelofibrosis), myelofibrosis associated with polycythemia vera (PPV-MF), or myelofibrosis associated with primary thrombocythemia (PET-MF), to treat disease-related splenomegaly or disease-related symptoms; 2. Graft-versus-host disease. For the treatment of patients aged 12 years and older with acute graft-versus-host disease (acute GVHD) or chronic graft-versus-host disease (chronic GVHD) who have insufficient response to corticosteroids or other systemic treatments. This drug was co-developed by Incyte and Novartis and was launched in the United States in November 2011.